|1.||Rengifo, Enrique: 7 articles (01/2015 - 10/2004)|
|2.||Carr, Adriana: 7 articles (01/2015 - 01/2011)|
|3.||Rengifo, Charles E: 7 articles (01/2015 - 01/2011)|
|4.||Kabayama, Kazuya: 7 articles (01/2012 - 02/2002)|
|5.||Blanco, Rancés: 6 articles (01/2015 - 01/2011)|
|6.||Cedeño, Mercedes: 6 articles (01/2015 - 01/2011)|
|7.||Lee, Young-Choon: 6 articles (08/2014 - 07/2006)|
|8.||Chung, Tae-Wook: 6 articles (08/2014 - 07/2006)|
|9.||Kim, Cheorl-Ho: 6 articles (08/2014 - 07/2006)|
|10.||Choi, Hee-Jung: 6 articles (08/2014 - 07/2006)|
12/01/2008 - "Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge."
07/15/1994 - "Murine B16 melanoma expresses the ganglioside GM3. "
03/29/1994 - "Mouse B16 melanoma cell line, GM-95 (formerly designated as MEC-4), deficient in sialyllactosylceramide was examined for its primary defect. "
02/01/1987 - "A monoclonal antibody, M2590, that recognizes hematoside (GM3) was used to analyze the immunostaining localization of GM3 of the surface of transformed and non-transformed hamster embryo fibroblasts and B16 melanoma cells. "
01/03/1986 - "Reactivity of mouse monoclonal antibody M2590 against B16 melanoma cells with chemically synthesized GM3 ganglioside."
01/01/1991 - "This fraction was highly specific for the hydrolysis of sialic acid from GM3 ganglioside, and was equally effective in fibroblasts from patients with mucolipidosis IV and in fibroblasts from controls."
05/15/1989 - "Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties."
01/04/1983 - "In sialidosis with partial beta-galactosidase deficiency, the sialidases of the lysosomes showed 3-5% activity toward hydrophilic substrates and 25% activity toward GM3 ganglioside as compared with sialidase activities of the controls. "
05/15/1989 - "In fibroblasts from patients with mucolipidosis IV (ML IV), both the Triton X-100- and the cholate-stimulated ganglioside GM3 sialidase activities were in the range of normal controls. "
05/15/1989 - "In fibroblasts from sialidosis patients, the cholate-stimulated ganglioside GM3 sialidase activity, but not that of the Triton-activated enzyme, was profoundly diminished. "
|3.||Lewis Lung Carcinoma
07/01/2006 - "Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells."
07/01/2006 - "To investigate the significance of the ganglioside GM3 in cancer malignancy, we established GM3-reconstituted cells by transfecting the cDNA of GM3 synthase into a GM3-deficient subclone of the 3LL Lewis lung carcinoma cell line (Uemura, S. "
10/15/1990 - "Treatment of Lewis lung carcinoma cells with 5 microM D-PDMP resulted in a time-dependent marked decrease in levels of all cellular GSLs (glucosylceramide, lactosylceramide, ceramide trihexoside, globoside, and ganglioside GM3). "
08/01/2007 - "The study suggested that GM3 ganglioside may have a crucial role in "downregulation" of the metastatic potential of bovine urothelial cancers."
04/01/2014 - "Racotumomab is a murine gamma-type anti-idiotype monoclonal antibody that specifically induces an antibody response against Neu-glycolyl GM3 ganglioside (NeuGcGM3), which is overexpressed in several solid tumors. "
01/01/2013 - "Our data suggest that the expression of N-glycolyl GM3 ganglioside could be related to the aggressive behavior of malignant cells, without depending on the tumor origin. "
01/01/2013 - "Specifically, some reports of 14F7 Mab (a highly specific Mab raised against N-glycolyl GM3 ganglioside) reactivity in human tumors have been recently published. "
01/01/2013 - "Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin."
|5.||Melanoma (Melanoma, Malignant)
11/01/2012 - "N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese."
06/01/2001 - "A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo."
08/01/1998 - "Lack of the induction of anti-ganglioside GM3 antibody in the patients with malignant melanoma in Japanese."
01/01/1994 - "Both VH and VL regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM3."
06/15/1991 - "Ganglioside GM3:GD3 ratio as an index for the management of melanoma."
|1.||N-Acetylneuraminic Acid (Sialic Acid)
|2.||CDw17 antigen (lactosylceramide)
|4.||RV 538 (PDMP)
|6.||Epidermal Growth Factor (EGF)